Drugs / CT-202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07545122 | Sep 2026 → Jan 2030 expected | colorectal cancer, triple-negative breast carcinoma, urothelial carcinoma | Context Therapeutics Inc. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | Context Therapeutics Inc. | Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 contexttherapeutics.com ↗ |
| 2026-05-18 | Context Therapeutics Inc. | Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 contexttherapeutics.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07545122 ↗ |